Morphosys announced the appointment of Lisa Rojkjaer, MD, as Vice President and Head of Clinical Development. 
Dr. Rojkjaer joins Morphosys from Novartis Pharma where she most recently held the position of Head of Medical Affairs - Hematology, Europe, following her appointment as global clinical program head for Exjade. Here she was responsible for all clinical activities in Europe for Novartis's Hematology portfolio including Gleevec and Exjade. Prior to her tenure at Novartis, she spent five years with Novo Nordisk, in Copenhagen, Denmark, and Princeton, U.S. as the Director of Global Medical Affairs Biopharmaceuticals and later Director, Clinical Development Hematology.